Janux Therapeutics, Inc. (JANX) income statement
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.31−0.40 (-3.73%)
Close on Nov 18, 2026Market cap $630.32MP/E –Yield –
Janux Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -598.1%
- Net margin
- -427.5%
- Return on equity, FY2025
- -11.5%
Financial strength
- Current ratio
- 16.35
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 46.2%
Valuation
- P/E ratio
- –
- Price to sales
- 26.26
- Price to book
- 0.68
- Dividend yield
- –
See a number that looks wrong?